NCT00408889已完成不适用
Prospective Evaluation of Predictors for Organ Failure Following Liver Transplantation
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 150
- 试验地点
- 1
研究概览
简要总结
Early organ failure occurs frequently and is difficult to predict. The study aims to define a predictive score for early transplant failure.
详细描述
Patients will be monitored 7 days following liver transplantation, including clinical scores, clinical chemistry, ultrasound findings and indocyaninegreen-clearance.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •orthotopic liver transplantation
- •age > 18 years
排除标准
- •allergy to indocyangreen
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Predictive factors of organ involvements and severity in inflammatory myopathyinflammatory myopathyJPRN-UMIN000040979agasaki University200
已完成
不适用
Delta qSOFA for Risk Stratification in Emergency Infected PatientsSepsisNCT02926664Societe Française de Medecine d'urgence512
进行中（未招募）
1 期
EVALUATION OF POTENTIAL PREDICTORS OF DISEASE PROGRESSION IN PATIENTS WITH aHUS, INCLUDING GENETICS, BIOMARKERS, ANDTREATMENTatypical Hemolytic-Uremic Syndrome (aHUS)MedDRA version: 19.1Level: LLTClassification code 10019515Term: Hemolytic uremic syndromeSystem Organ Class: 100000004851EUCTR2015-003135-35-DEAlexion Pharmaceuticals, Inc.330
进行中（未招募）
1 期
EVALUATION OF POTENTIAL PREDICTORS OF DISEASE PROGRESSION IN PATIENTS WITH aHUS, INCLUDING GENETICS, BIOMARKERS, AND TREATMENTatypical Hemolytic-Uremic Syndrome (aHUS)MedDRA version: 19.0Level: LLTClassification code 10019515Term: Hemolytic uremic syndromeSystem Organ Class: 100000004851EUCTR2015-003135-35-BEAlexion Pharmaceuticals, Inc.330
进行中（未招募）
1 期
EVALUATION OF POTENTIAL PREDICTORS OF DISEASE PROGRESSION IN PATIENTS WITH aHUS, INCLUDING GENETICS, BIOMARKERS, AND TREATMENTatypical Hemolytic-Uremic Syndrome (aHUS)MedDRA version: 19.1 Level: LLT Classification code 10019515 Term: Hemolytic uremic syndrome System Organ Class: 100000004851EUCTR2015-003135-35-GBAlexion Pharmaceuticals, Inc.67